Today: 24 June 2026
Browse Category

Pharmaceuticals 26 October 2025 - 4 November 2025

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Billion-Dollar Brawl: Novo Nordisk and Pfizer Clash in High-Stakes Obesity Drug Takeover

Novo Nordisk raised its offer for Metsera to about $10 billion, topping Pfizer’s $8.1 billion bid. Metsera’s board labeled Novo’s bid “superior,” triggering a two-day window for Pfizer to respond. Pfizer has filed lawsuits in Delaware and federal court to block Novo’s challenge. Shares in Metsera jumped 20% after the news, while Novo’s stock slipped.
4 November 2025
···
Fentanyl ‘Nuke’ & Anti-Woke Crusade: Palantir CEO’s Wild Earnings Call Fuels $490 B AI Surge

Fentanyl ‘Nuke’ & Anti-Woke Crusade: Palantir CEO’s Wild Earnings Call Fuels $490 B AI Surge

Palantir Technologies reported Q3 2025 revenue of nearly $1.2 billion, up 63% year-on-year, and raised full-year guidance to $4.4 billion. CEO Alex Karp declared Palantir “the first company to be completely anti-woke,” defended its work with ICE and Israel, and told critics to “get some popcorn.” Shares surged 200% in 2025 but fell 7% after earnings on valuation concerns.
4 November 2025
··
Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer’s Q3 Shocker: Earnings Beat, Outlook Raised, and a $7 Billion Obesity Drug Gambit

Pfizer reported Q3 2025 adjusted earnings of $0.87 per share, beating estimates, with revenue at $16.65–$16.7 billion. The company raised its full-year profit outlook to $3.00–$3.15 EPS. Sales of COVID products plunged, but demand for Eliquis and Vyndaqel rose. Pfizer sued Novo Nordisk over a $7.3 billion bid for obesity drugmaker Metsera; a court hearing is set for Nov. 4.
4 November 2025
···
Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer (PFE) Stock at a Crossroads: Big Dividend, Weight-Loss Gamble & 2025 Outlook

Pfizer shares traded at $24.65 on Nov. 3, 2025, down about 3% year-to-date and over 50% from pandemic highs. The company reports Q3 results Nov. 4, with analysts expecting $16.6 billion in revenue and $0.66 EPS. Pfizer completed a $43 billion Seagen acquisition and is in a bidding war with Novo Nordisk over Metsera. The quarterly dividend is $0.43 per share, yielding around 7%.
3 November 2025
··
Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

Rani Therapeutics (RANI) Stock Skyrockets on Biotech Breakthrough: Inside the Surge and What’s Next

Rani Therapeutics shares surged over 300% in a month, jumping to $2.20–$2.50 after announcing a partnership with Chugai Pharmaceutical worth up to $1.085 billion. The deal brought $10 million upfront and extended Rani’s cash runway into 2028 with a $60.3 million financing. Analyst targets rose as high as $11. Trading volume spiked tenfold, with the stock breaking key technical levels.
3 November 2025
··
Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Pfizer Stock Surges on Trump Deal & Obesity Drug Drama – Is a Comeback Coming?

Pfizer shares closed at $24.65 on Oct. 31, 2025, rebounding from September lows after a White House drug pricing deal but still near multi-year lows. The company is suing Novo Nordisk over an $8.5 billion bid for obesity drugmaker Metsera, which undercut Pfizer’s own $7.3 billion offer. Investors await Pfizer’s Q3 earnings on Nov. 4 as the firm faces a sharp drop in COVID-related sales.
2 November 2025
·
Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Eli Lilly Stock Pre-Market Preview: Will Obesity-Drug Boom Send LLY to New Highs? (Nov 3, 2025)

Eli Lilly shares closed near $863 on Oct. 31, up about 10% for the month and close to a 52-week high. Q3 revenue jumped 54% to $17.6 billion, driven by surging demand for GLP-1 drugs Mounjaro and Zepbound, with U.S. GLP-1 market share at 57%. Management raised 2025 sales and EPS guidance sharply. The company recently won FDA approval for Inluriyo and expanded Walmart access for Zepbound.
2 November 2025
·
Rani Therapeutics (RANI) Stock Skyrockets ~200% on $1B Pharma Deal – Will the Rally Last?

Rani Therapeutics Stock Explodes on Obesity-Drug Breakthrough – Analysts Eye $10+ Targets

Rani Therapeutics stock surged 330% in October, closing at $2.20 on Nov. 1 after announcing a $1.085 billion licensing deal with Chugai and positive preclinical data for its oral semaglutide pill. The company, which has no approved products or meaningful revenue, raised $60.3 million in a private placement. Analysts rate RANI a Buy, but warn of high risk due to ongoing losses and no product sales.
1 November 2025
·
AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

AbbVie reported Q3 2025 revenue of $15.78 billion, up 9.1% year-over-year, and raised its full-year EPS outlook after new drugs offset Humira’s decline. Shares traded near $228 in late October, up 28% year-to-date, and the board approved a 5.5% dividend increase for 2026. Skyrizi and Rinvoq sales surged, while the FDA expanded Rinvoq’s indications. AbbVie also announced over $10 billion in acquisitions and new manufacturing investments.
31 October 2025
··
Moderna Stock Soars on Buyout Buzz – Can New Vaccines Fuel a Comeback?

Moderna Stock Soars on Buyout Buzz – Can New Vaccines Fuel a Comeback?

Moderna shares surged 12% to near $27.50 on Oct. 30, 2025, after reports of takeover talks with a large drugmaker. The rally follows a STAT News report on possible deals, but Moderna declined comment. Despite gains, the stock remains down about 37% year-to-date. Recent FDA approvals include updated COVID and RSV vaccines, but falling COVID demand has cut 2025 revenue and forced cost reductions.
30 October 2025
··
Pfizer Stock Soars: Trump’s Drug-Price Deal and $7B Weight-Loss Bet Spark Rally

Pfizer Stock Soars: Trump’s Drug-Price Deal and $7B Weight-Loss Bet Spark Rally

Pfizer shares traded near $24.20 on Oct. 30, 2025, flat for the week and close to the low end of their 52-week range. The stock surged 15% in late September after Pfizer agreed to cut Medicaid drug prices and announced a $7.3 billion deal to acquire obesity-drug maker Metsera. Rival Novo Nordisk countered with a higher bid for Metsera. Q3 earnings are due Nov. 4, with analysts expecting a sharp year-over-year decline.
30 October 2025
··
Novo Nordisk (NVO) Stock Tanks as Weight-Loss Empire Faces Boardroom Coup and Fierce Rivalry

Novo Nordisk hijacks Pfizer’s Metsera deal with a $9B bid – obesity-drug war heats up

Novo Nordisk launched an $8.5 billion unsolicited bid for obesity drugmaker Metsera, topping Pfizer’s $7.3 billion agreed deal. Novo’s offer values Metsera at $56.50 per share in cash plus up to $21.25 in milestone payments. Metsera shares jumped 18% premarket, while Novo’s stock fell 3%. Pfizer called Novo’s bid “reckless” and warned it could harm competition.
30 October 2025
····
Merck (MRK) Stock Could Skyrocket: Key Drug Approvals & Analyst Targets Unveiled

Merck (MRK) Stock Dips on Earnings Beat — Will Pipeline Boost Spur a Rally?

Merck shares fell about 2% after hours Oct. 30 despite Q3 revenue of $17.28 billion and $2.58 adjusted EPS, both above estimates. Keytruda sales rose 10% to $8.1 billion. The company narrowed its 2025 sales outlook and raised profit guidance. Recent milestones include FDA approval of subcutaneous Keytruda and the $10 billion acquisition of Verona Pharma.
30 October 2025
···
Big Pharma’s Billion-Dollar Bet: Inside Eli Lilly’s $5B Virginia Factory and America’s New Drug Manufacturing Boom

Eli Lilly Stock on Fire: GLP-1 Bonanza, Big Earnings & AI Pivot Drive Rally

Eli Lilly reported Q3 2025 revenue of $17.60 billion, up 54% year-over-year, and raised full-year EPS guidance to $23.00–23.70. Shares closed at $813.53 on Oct. 29, down 2% over the week after hitting highs above $850 earlier in the month. The FDA approved Inluriyo for metastatic breast cancer, and the EU cleared Kisunla for early Alzheimer’s. Wall Street’s average 12-month price target stands near $939.
30 October 2025
···
Ernexa Therapeutics (ERNA) Skyrockets on Cancer Therapy Deal – Will Rally Last?

Ernexa Therapeutics (ERNA) Skyrockets on Cancer Therapy Deal – Will Rally Last?

Ernexa Therapeutics shares jumped nearly 50% to $1.80 intraday on October 29, 2025, after announcing a manufacturing partnership with Cellipont Bioservices to advance its ovarian cancer cell therapy, ERNA-101, toward clinical trials. Trading volume surged. Despite the rally, ERNA stock remains down about 58% in 2025 and 89% year-on-year after previous setbacks and a reverse stock split.
29 October 2025
··
Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Pharma Giants Converge in Frankfurt – Obesity Drug Boom & Tech Innovations Fuel $1.7 Trillion Industry Future

Over 62,000 pharmaceutical professionals from more than 170 countries are attending CPHI Frankfurt 2025, where executives are meeting to address global supply chain, regulation, and innovation challenges. Eli Lilly’s GLP-1 drugs generated $6.1 billion in Q1 2025, overtaking Novo Nordisk in the U.S. weight-loss drug market. Pharma giants are investing heavily as the global obesity treatment market is projected to reach $100 billion by 2030.
28 October 2025
····
Pfizer Stock Surges 15% on Trump’s Pricing Pact & $7.3B Obesity Deal – Can the Rally Last?

Pfizer (PFE) Stock Rebounds on Trump Drug Deal & Obesity Gamble – Can the Rally Last?

Pfizer shares traded near $24.76 on Oct. 24, up about 9% from their 52-week low but still down for the year. The stock jumped over 6% in late September after Pfizer reached a deal with the Trump administration to cut Medicaid drug prices, easing regulatory risk. Pfizer reports Q3 results Nov. 4, with analysts expecting lower earnings due to falling COVID product sales.
27 October 2025
··
Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Novartis’ $12B Biotech Buyout Shakes Up Avidity Biosciences (RNA) – Is the Rare-Disease Stock Set to Soar?

Novartis will acquire Avidity Biosciences for $12 billion in cash, offering $72 per share—a 46% premium over Avidity’s last close. Avidity’s stock, which ended Friday at $49.15, is expected to jump sharply when markets open. Novartis is targeting Avidity’s RNA therapies for rare muscle diseases, including a lead drug nearing FDA submission. The deal was announced Sunday, Oct. 26, 2025.
26 October 2025
····
1 … 37 38 39 40 41 42

Stock Market Updates

KB Home (NYSE:KBH) rises after hours as traders look to H2 delivery gains

KB Home (NYSE:KBH) rises after hours as traders look to H2 delivery gains

24 June 2026
KB Home jumped 4% after hours as investors bet on a back-loaded 2026 delivery plan, despite missing profit estimates; the builder must deliver 26% more homes in the second half to hit its target, with margins expected to edge up, while shares still trade below book value and buybacks continue.
Delta eyes higher margins as jet fuel drops; fares may follow

Delta eyes higher margins as jet fuel drops; fares may follow

24 June 2026
Delta CEO warns lower jet fuel prices alone won’t cut fares unless airlines can add more flights, as U.S. carriers paid $6.47 billion for fuel in April—up 78% from last year—while capacity growth is just 0.4% for Q3; Delta shares last traded at $86.72, up 81 cents.
IREN stock falls as Wall Street stays split on AI cloud payoff

IREN stock falls as Wall Street stays split on AI cloud payoff

24 June 2026
IREN plunged 3.78% to $54.72 as tech stocks tumbled on AI spending worries, but analysts remain split with targets from $36 to $100; Microsoft’s $9.7B contract and a new $3.65B GPU financing facility drive bullish bets, while risks from uncontracted revenue targets and delivery timelines leave the stock highly volatile.
Blue Owl (NYSE:OWL) trades near year low after new credit fund filing

Blue Owl (NYSE:OWL) trades near year low after new credit fund filing

24 June 2026
Blue Owl Capital plunged 3.4% to $8.91 on volume 68% above average, nearing its 52-week low, as investors weighed a 10.3% dividend yield against slipping fee-paying assets, $1.2 billion in BDC redemptions, and 13.9% software-credit exposure, despite Blue Owl Credit Income Corp. reporting $19.4 billion NAV, $11.6 billion liquidity, and positive year-to-date returns in a new SEC filing.
Go toTop